BIOVF News and Press, Swedish Orphan Biovit Ord From 10/22/20

The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2020 Q3 earnings call. For further details see: Swedish Orphan Biovitrum AB (publ) 2020 Q3 - Results - Earnings Call Presentation

Sobi publishes report for the third quarter 2020 PR Newswire STOCKHOLM, Oct. 22, 2020 STOCKHOLM , Oct. 22, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the third quarter 2020. Total revenue for...

A Phase 3 clinical trial evaluating Swedish Orphan Biovitrum AB's (BIOVF) Doptelet (avatrombopag) in solid tumor patients with chemo-induced thrombocytopenia (low blood platelets) failed to achieve the primary endpoint.The 122-subject study did not meet the composite endpoint of avoiding plat...

Sobi announces topline phase 3 data of avatrombopag for the treatment of Chemotherapy-Induced Thrombocytopenia PR Newswire STOCKHOLM, Oct. 9, 2020 STOCKHOLM , Oct. 9, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today anno...

Invitation - Presentation of Sobi's Q3 2020 results PR Newswire STOCKHOLM, Oct. 7, 2020 STOCKHOLM , Oct. 7, 2020 /PRNewswire/ -- On 22 October, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the third quar...

After the company reported its gout drug, SEL-212, failed to meet its primary endpoint in a mid-stage clinical trial, shares in Selecta Biosciences (NASDAQ: SELB) traded 33.5% lower on Thursday. The biotech stock licensed SEL-212 -- a combination of Selecta's synthetic vacci...

Sobi and Selecta Biosciences announce topline data of SEL-212 from the phase 2 COMPARE study supporting the potential for important clinical improvement in patients with Chronic Refractory Gout - All data consistent with stronger performance of SEL-212 versus pegloticase - N...

Selecta Biosciences (SELB) and its collaborating partner Swedish Orphan Biovitrum (BIOVF) announced topline data from Phase 2 COMPARE trial comparing SEL-212, a combination of Selecta’s ImmTOR immune tolerance platform and therapeutic uricase enzyme (pegadricase), to Horizon Therapeuti...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval of Swedish Orphan Biovitrum's ( OTCPK:BIOVF ) for the treatment of adults with alkaptonuria , a rare inherited disorder caused by the accumulation of homogentisic acid in the body due to ...

The European Medicines Agency's advisory group CHMP has adopted a negative opinion against approval of Swedish Orphan Biovitrum AB's ( OTCPK:BIOVF ) Gamifant (emapalumab) for the treatment of primary hemophagocytic lymphohistiocytosis (HLH) in children under the age of 18. More news on...